Evidence map›Paper›PMID 40535072›Full record

ReviewTranslational lung cancer research2025

Opportunities and challenges in lung cancer care in the era of large language models and vision language models.

Yi Luo, Hamed Hooshangnejad, Wilfred Ngwa, Kai Ding

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi LuoDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Hamed HooshangnejadDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Wilfred NgwaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA.
Kai DingDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA.

Funding

Spacer Enabled Robust Radiation Therapy (SERRT)R37CA229417 · NCI · JOHNS HOPKINS UNIVERSITY · PI DING, KAI · 2018 to 2021
$1.5M
CaREER: Cancer Research Education Excellence in RadiotherapyR25CA288263 · NCI · JOHNS HOPKINS UNIVERSITY · PI Heng Li, Akila Viswanathan · 2024 to 2026
$848k
NCI NIH HHS R25 CA288263NCI NIH HHS R37 CA229417
6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related deaths globally. Over the past decade, the development of artificial intelligence (AI) has significantly propelled lung cancer care, particularly in areas such as lung cancer early diagnosis, survival prediction, recurrence prediction, medical image processing, medical image registration, medical visual question answering, clinical report writing, medical image generation, and multimodal integration. This review aims to provide a comprehensive summary of the various AI methods utilized in lung cancer care, with a particular emphasis on machine learning and deep learning techniques. Moreover, with the advent and widespread application of large language models (LLMs), vision language models (VLMs), and multimodal integration for downstream clinical tasks, we explore the current landscape these cutting-edge AI tools offer. However, it also presents both significant challenges and opportunities, including data privacy risks, inherent biases that may exacerbate healthcare disparities, model hallucinations, ethical implications, implementation costs, and the lack of standardized evaluation metrics. Furthermore, the translation of these technologies from experimental research to clinical implementation demands comprehensive validation protocols and multidisciplinary collaboration to guarantee patient safety, therapeutic efficacy, and equitable healthcare delivery. This review emphasizes the critical role of AI in enhancing our understanding and management of lung cancer, ultimately striving for precision medicine and equitable healthcare worldwide.

Indexed as

Large language model (LLM)lung cancer carevision language model (VLM)

Identifiers

PMID40535072
PMCPMC12170128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.